Accessed through the Hayes Knowledge Center, the Evidence Analysis Solution addresses the following fundamental questions to help our clients determine coverage positions:
Focus of the Report: This report evaluates the use of voretigene neparvovec-rzyl (Luxturna) for the treatment of vision loss due to inherited retinal dystrophies (IRDs) from confirmed biallelic RPE65 mutations.
Technology Description: Voretigene neparvove…
Focus of the Report: This report focuses on amniotic allograft (AA) for treatment or prevention of tendon and ligament injuries.
Technology Description: AA is prepared from sheets of amniotic membrane obtained shortly after caesarean delivery. For some products, amniotic membrane is de…
Focus of the Report: The use of minimally invasive sacroiliac joint (SIJ) fusion with the iFuse Implant System (SI-Bone Inc.) for the treatment of adults with SIJ dysfunction who have not experienced adequate relief from nonsurgical management (NSM).
Technology Description: The iFuse i…
Focus of the Report: This report focuses on matrix-induced autologous chondrocyte implantation (MACI) for the treatment of patients with chondral defects of the knee.
Technology Description: MACI is a multi-stage procedure that involves 2 surgeries. During an initial arthroscopic surge…
Focus of the Report: The use of deep brain stimulation (DBS) for treatment of refractory obsessive-compulsive disorder (OCD).
Technology Description: DBS therapy uses mild electrical impulses to regulate electrical activity of neural circuits. Patients undergo surgery to implant a med…
Focus of the Report: This report focuses on bioimpedance analysis (BIA) for diagnosis, predicting development, selection of treatment, and monitoring of lymphedema (LE).
Technology Description: BIA measures the differential impedance (resistance) to low level electrical current to eval…
Focus of the Report: This report evaluates the efficacy and safety of the gene replacement therapy onasemnogene abeparvovec-xioi (Zolgensma or AVXS-101) for treatment of patients with spinal muscular atrophy (SMA) type 1.
Technology Description: Onasemnogene abeparvovec is a single-dos…
Focus of the Report: This report compares the effectiveness and safety of skin substitutes (cellular and acellular) as an addition to standard wound care (SWC) with SWC alone and compared with the adjunct use of alternative skin substitute products to treat chronic or nonhealing venous leg ulcers in adults.
If you have a Hayes login, click here to view the full report on the Knowledge Center.
Focus of the Report: This report evaluates the use of tisagenlecleucel (Kymriah) for the treatment of relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) or r/r diffuse large B-cell lymphoma (DLBCL).
Technology Description: Tisagenlecleucel therapy is a form of chime…